CacyBP/SIP promotes tumor progression by regulating apoptosis and arresting the cell cycle in osteosarcoma

Zhao,Ming; Zhang,Run‑Zi; Qi,Dian‑Wen; Chen,Hong‑Yi; Zhang,Guo‑Chuan

doi:10.3892/etm.2020.8843

CacyBP/SIP promotes tumor progression by regulating apoptosis and arresting the cell cycle in osteosarcoma

Authors:
- Ming Zhao
- Run‑Zi Zhang
- Dian‑Wen Qi
- Hong‑Yi Chen
- Guo‑Chuan Zhang
View Affiliations

Affiliations: Department of Musculoskeletal Tumors, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China
Published online on: June 5, 2020 https://doi.org/10.3892/etm.2020.8843
Pages: 1397-1404
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma (OS) is the most common primary malignant bone tumor in pediatric and adolescent patients. The calcyclin‑binding protein/Siah‑1‑interacting protein (CacyBP/SIP) performs an essential function in cell proliferation and apoptosis. The present study investigated the effect of CacyBP/SIP in OS cell proliferation and apoptosis. CacyBP/SIP mRNA expression levels were evaluated in four OS cell lines by quantitative PCR. CacyBP/SIP expression was downregulated in Saos‑2 cells using a lentivirus transfection system and the transfection efficiency was analyzed. The effects of CacyBP/SIP downregulation on Saos‑2 cell proliferation and colony‑formation ability were evaluated by MTT and colony‑formation assays. The effect of CacyBP/SIP knockdown on Saos‑2 cell cycle and apoptosis was analyzed by ﬂow cytometry cell sorting. The Cancer Genome Atlas (TCGA) data was analyzed for validation. Human OS cell lines Saos‑2, MG‑63, HOS and U20S expressed CacyBP/SIP mRNA. CacyBP/SIP knockdown significantly inhibited cell proliferation and colony‑formation ability. G1/S phase arrest was induced by CacyBP/SIP downregulation, which also resulted in the downregulation of CDK and cyclins and the upregulation of p21. In addition, CacyBP/SIP downregulation induced Saos‑2 cell apoptosis mediated by Bax and Bcl‑2. High expression of CacyBP/SIP was significantly associated with poor prognosis in TCGA sarcoma database. Thus, CacyBP/SIP performs important functions in the proliferation and apoptosis of human OS cells.

View Figures

View References

1	Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res. 152:3–13. 2009.PubMed/NCBI View Article : Google Scholar
2	Bernthal NM, Federman N, Eilber FR, Nelson SD, Eckardt JJ, Eilber FC and Tap WD: Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. Cancer. 118:5888–5893. 2012.PubMed/NCBI View Article : Google Scholar
3	Grignani G, Palmerini E, Dileo P, Asaftei SD, D'Ambrosio L, Pignochino Y, Mercuri M, Picci P, Fagioli F, Casali PG, et al: A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: An Italian Sarcoma Group study. Ann Oncol. 23:508–516. 2012.PubMed/NCBI View Article : Google Scholar
4	Zhang Y, Yang J, Zhao N, Wang C, Kamar S, Zhou Y, He Z, Yang J, Sun B, Shi X, et al: Progress in the chemotherapeutic treatment of osteosarcoma. Oncol Lett. 16:6228–6237. 2018.PubMed/NCBI View Article : Google Scholar
5	Grignani G, Palmerini E, Ferraresi V, D'Ambrosio L, Bertulli R, Asaftei SD, Tamburini A, Pignochino Y, Sangiolo D, Marchesi E, et al: Italian Sarcoma Group: Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: A non-randomised phase 2 clinical trial. Lancet Oncol. 16:98–107. 2015.PubMed/NCBI View Article : Google Scholar
6	Filipek A and Kuźnicki J: Molecular cloning and expression of a mouse brain cDNA encoding a novel protein target of calcyclin. J Neurochem. 70:1793–1798. 1998.PubMed/NCBI View Article : Google Scholar
7	Filipek A and Wojda U: p30, a novel protein target of mouse calcyclin (S100A6). Biochem J. 320:585–587. 1996.PubMed/NCBI View Article : Google Scholar
8	Topolska-Woś AM, Chazin WJ and Filipek A: CacyBP/SIP - Structure and variety of functions. Biochim Biophys Acta. 1860:79–85. 2016.PubMed/NCBI View Article : Google Scholar
9	Zhai H, Shi Y, Jin H, Li Y, Lu Y, Chen X, Wang J, Ding L, Wang X and Fan D: Expression of calcyclin-binding protein/Siah-1 interacting protein in normal and malignant human tissues: An immunohistochemical survey. J Histochem Cytochem. 56:765–772. 2008.PubMed/NCBI View Article : Google Scholar
10	Shi H, Gao Y, Tang Y, Wu Y, Gong H, Du J, Zheng B, Hu J, Shi Q and Yu R: CacyBP/SIP protein is important for the proliferation of human glioma cells. IUBMB Life. 66:286–291. 2014.PubMed/NCBI View Article : Google Scholar
11	Rosińska S, Leśniak W and Filipek A: Distinct effect of CacyBP/SIP on the ERK1/2-CREB-BDNF pathway in undifferentiated and differentiated neuroblastoma NB2a cells. Neurochem Int. 97:65–72. 2016.PubMed/NCBI View Article : Google Scholar
12	Chen X, Zheng P, Xue Z, Li J, Wang W, Chen X, Xie F, Yu Z and Ouyang X: CacyBP/SIP enhances multidrug resistance of pancreatic cancer cells by regulation of P-gp and Bcl-2. Apoptosis. 18:861–869. 2013.PubMed/NCBI View Article : Google Scholar
13	Fu C, Wan Y, Shi H, Gong Y, Wu Q, Yao Y, Niu M, Li Z and Xu K: Expression and regulation of CacyBP/SIP in chronic lymphocytic leukemia cell balances of cell proliferation with apoptosis. J Cancer Res Clin Oncol. 142:741–748. 2016.PubMed/NCBI View Article : Google Scholar
14	Zhai H, Shi Y, Chen X, Wang J, Lu Y, Zhang F, Liu Z, Lei T and Fan D: CacyBP/SIP promotes the proliferation of colon cancer cells. PLoS One. 12(e0169959)2017.PubMed/NCBI View Article : Google Scholar
15	Ning X, Sun S, Hong L, Liang J, Liu L, Han S, Liu Z, Shi Y, Li Y, Gong W, et al: Calcyclin-binding protein inhibits proliferation, tumorigenicity, and invasion of gastric cancer. Mol Cancer Res. 5:1254–1262. 2007.PubMed/NCBI View Article : Google Scholar
16	Sun S, Ning X, Liu J, Liu L, Chen Y, Han S, Zhang Y, Liang J, Wu K and Fan D: Overexpressed CacyBP/SIP leads to the suppression of growth in renal cell carcinoma. Biochem Biophys Res Commun. 356:864–871. 2007.PubMed/NCBI View Article : Google Scholar
17	Topolska-Woś AM, Rosińska S and Filipek A: MAP kinase p38 is a novel target of CacyBP/SIP phosphatase. Amino Acids. 49:1069–1076. 2017.PubMed/NCBI View Article : Google Scholar
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Δ Δ C(T)) Method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
19	Chai R, Yu X, Tu S and Zheng B: Depletion of UBA protein 2-like protein inhibits growth and induces apoptosis of human colorectal carcinoma cells. Tumour Biol. 37:13225–13235. 2016.PubMed/NCBI View Article : Google Scholar
20	Henderson T, Chen M, Darrow MA, Li CS, Chiu CL, Monjazeb AM, Murphy WJ and Canter RJ: Alterations in cancer stem-cell marker CD44 expression predict oncologic outcome in soft-tissue sarcomas. J Surg Res. 223:207–214. 2018.PubMed/NCBI View Article : Google Scholar
21	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell 171: 950-965.e928, 2017.
22	Hartigan JA and Wong MA: A K-means clustering algorithm. Appl Stat. 28:100–108. 2013.
23	Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.PubMed/NCBI View Article : Google Scholar
24	Vats P, Ray K, Majumadar D, Amitabh Joseph DA, Bayen S, Akunov A, Sarbaev A and Singh SB: Changes in cardiovascular functions, lipid profile, and body composition at high altitude in two different ethnic groups. High Alt Med Biol. 14:45–52. 2013.PubMed/NCBI View Article : Google Scholar
25	Zhai HH, Meng J, Wang JB, Liu ZX, Li YF and Feng SS: CacyBP/SIP nuclear translocation induced by gastrin promotes gastric cancer cell proliferation. World J Gastroenterol. 20:10062–10070. 2014.PubMed/NCBI View Article : Google Scholar
26	Ning X, Sun S, Zhang K, Liang J, Chuai Y, Li Y and Wang X: S100A6 protein negatively regulates CacyBP/SIP-mediated inhibition of gastric cancer cell proliferation and tumorigenesis. PLoS One. 7(e30185)2012.PubMed/NCBI View Article : Google Scholar
27	Zhang Y, Wang S, Qian W, Ji D, Wang Q, Zhang Z, Wang S, Ji B, Fu Z and Sun Y: uc.338 targets p21 and cyclin D1 via PI3K/AKT pathway activation to promote cell proliferation in colorectal cancer. Oncol Rep. 40:1119–1128. 2018.PubMed/NCBI View Article : Google Scholar
28	Merli M, Benassi MS, Gamberi G, Ragazzini P, Sollazzo MR, Molendini L, Magagnoli G, Ferrari C, Maltarello MC and Picci P: Expression of G₁ phase regulators in MG-63 osteosarcoma cell line. Int J Oncol. 14:1117–1121. 1999.PubMed/NCBI View Article : Google Scholar
29	Adams PD, Sellers WR, Sharma SK, Wu AD, Nalin CM and Kaelin WG Jr: Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol Cell Biol. 16:6623–6633. 1996.PubMed/NCBI View Article : Google Scholar
30	Song Z, Lin J, Sun Z, Ni J and Sha Y: RNAi-mediated downregulation of CDKL1 inhibits growth and colony-formation ability, promotes apoptosis of human melanoma cells. J Dermatol Sci. 79:57–63. 2015.PubMed/NCBI View Article : Google Scholar
31	el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell. 75:817–825. 1993.PubMed/NCBI View Article : Google Scholar